Abstract
We studied the clinical effect of a new cephalosporin, cefodizime (THR-221), in 2 patients with acute simple pyelonephritis, in 1 patient with acute simple cystitis and in 14 patients with complicated urinary tract infection. Cefodizime was administered by i. v. drip infusion at a dose of 1 g twice a day. Two patients with acute simple pyelonephritis and 14 with complicated urinary tract infection were evaluated by the criteria of the UTI Committee. The clinical effect of cefodizime in the 2 patients with acute simple pyelonephritis was excellent. In patients with complicated urinary tract infection, clinical effect was excellent in 6 cases, moderate in 4 and poor in 4, with an overall clinical efficacy rate of 71.4%.
During the treatment with cefodizime, no side-effects were seen. In laboratory findings, transient elevation of LAP was observed in one patient.
